Lori C Morton

This inventor holds 17 USPTO granted patents and 17 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Regeneron Pharmaceuticals, Inc., Regeneran Pharmaceuticals, Inc.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lori C Morton. Retrieved from https://idiyas.com/inventor/lori-c-morton

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 17)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 5 (Patent Applications = 16)

Average Co-Inventor Count = 4.4

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

Tarrytown, NY (US) (2020)
Chappaqua, NY (US) (2017 - 2024)

Company Filing History:

16 out of 1,482

Regeneron Pharmaceuticals, Inc.

patents

1 out of 49

Regeneran Pharmaceuticals, Inc.

patents

Years Active: 2017-2026

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12653168 - Complement Factor H Gene Knockout Rat as a Model of C3 Glomerulopathy (2026-06-16),

2. 12325752 - Immunoglobulin proteins that bind to NPR1 agonists (2025-06-10),

3. 12317874 - Method of using a genetically modified mouse that expresses human albumin (2025-06-03),

4. 12304969 - Factor XI A2 domain-binding antibodies and methods of use thereof (2025-05-20),

5. 12201096 - Non-human animals comprising a humanized coagulation factor 12 locus (2025-01-21),

6. 12068729 - Anti-factor XII/XIIa antibodies and uses thereof (2024-08-20),

7. 12030935 - Anti-PDGF-B antibodies and pharmaceutical composition thereof (2024-07-09),

8. 11820826 - Anti-NPR1 antibodies and uses thereof (2023-11-21),

9. 11737435 - Non-human animals comprising a humanized coagulation factor 12 locus (2023-08-29),

10. 11634480 - Human antibodies to GREM1 (2023-04-25),

11. 11622547 - Genetically modified mouse that expresses human albumin (2023-04-11),

12. 11306148 - Anti-NPR1 antibodies and uses thereof (2022-04-19),

13. 10765762 - Humanized model of kidney and liver disorders (2020-09-08),

14. 10526403 - Anti-activin A antibodies and uses thereof (2020-01-07),

15. 10377817 - Human antibodies to GREM1 (2019-08-13),

Title: The Innovations of Lori C. Morton: Pioneering Advances in Biomedical Science

Introduction: Lori C. Morton, based in Chappaqua, NY, is a prolific inventor with 15 patents to her name. Her groundbreaking work primarily focuses on innovative methods that intertwine genetics and biomedical applications. Lori has significantly contributed to the understanding and treatment of blood clotting disorders, utilizing her expertise to develop novel solutions.

Latest Patents: Among her most recent patents, Lori has developed a method that employs a genetically modified mouse designed to express human albumin. This innovation involves non-human animal genomes, cells, and species that incorporate a humanized albumin locus. These advancements allow for the assessment of in vivo efficacy of human-albumin-targeting reagents, including designed nuclease agents targeting human albumin. Additionally, she has created antibodies binding to the A2 domain of Factor XI, demonstrating potential therapeutic applications for blood clotting diseases while preserving hemostasis. These antagonist antibodies may serve as vital treatments for conditions characterized by excessive clot formation, such as atrial fibrillation.

Career Highlights: Lori's career is marked by her tenure at Regeneron Pharmaceuticals, Inc., where her research excels in the intersection of genetics and therapeutic development. Her contributions have propelled advancements in both scientific understanding and practical applications in the biomedical field.

Collaborations: Throughout her career, Lori has worked alongside notable colleagues, including Dan Chalothorn and Jesper Gromada, forming a collaborative network that fosters innovative ideas and solutions in patent development.

Conclusion: Lori C. Morton exemplifies the spirit of innovation in the life sciences sector. Her patents not only reflect her ingenuity but also her commitment to improving medical outcomes through targeted therapeutic strategies. As she continues to pioneer in her field, her work remains a testament to the impact of innovations in healthcare.

Profile summary based on public USPTO records.